This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

Targeted Protein Degradation: From Chemical Biology to Drug Discovery

Targeted Protein Degradation: From Chemical Biology to Drug Discovery

Tuesday, September 24, 2019, 8:30 AM - 6:00 PM

The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York

Presented By

Biochemical Pharmacology Discussion Group

The New York Academy of Sciences

 

The majority of disease-causing proteins are not amenable to modulation by conventional pharmacological methods. In recent years an alternative therapeutic strategy known as targeted protein degradation has emerged with the potential to inhibit these “undruggable” proteins. This method utilizes chimeric, tripartite molecules that bind to the protein of interest, thereby promoting its polyubiquitination and subsequent proteosomal degradation. These chimeras can be designed to target a wide range of proteins, and offer the advantage of completely ablating both catalytic and scaffolding functions. Moreover, recent data indicates that these molecules can be developed into effective oral agents, making them therapeutically viable.

This symposium will highlight the latest advances in the field of targeted protein degradation and showcase the benefits of this approach over traditional small molecule inhibitors.

Registration

Member
By 08/16/2019
$90
After 08/16/2019
$130
Nonmember Academia, Faculty, etc.
By 08/16/2019
$180
After 08/16/2019
$260
Nonmember Corporate, Other
By 08/16/2019
$250
After 08/16/2019
$350
Nonmember Not for Profit
By 08/16/2019
$180
After 08/16/2019
$260
Nonmember Student, Undergrad, Grad, Fellow
By 08/16/2019
$100
After 08/16/2019
$145
Member Student, Post-Doc, Fellow
By 08/16/2019
$50
After 08/16/2019
$70

Scientific Organizing Committee

Lynn M. Abell, PhD
Agios
Matthew Calabrese, PhD
Pfizer
Eric Fischer, PhD,
Dana-Farber Cancer Center
Adam Gilbert, PhD
Pfizer
Matthew Medeiros, PhD
Agios
Claire Steppan, PhD,
Pfizer
Sara Donnelly, PhD,
The New York Academy of Sciences
Sonya Dougal, PhD,
The New York Academy of Sciences

Keynote Speaker

James Bradner, MD,  Novartis Institutes for BioMedical Research
James Bradner, MD,
Novartis Institutes for BioMedical Research

Speakers

Danette Daniels
Dannette Daniels, PhD
Promega
Eric Fischer, PhD  Dana-Farber Cancer Center, Harvard Medical School
Eric Fischer, PhD
Dana-Farber Cancer Center, Harvard Medical School
Andreas Martin
Andreas Martin, PhD
University of California, Berkeley
Michael Rape
Michael Rape, PhD
University of California, Berkeley
Shaomeng Wang
Shaomeng Wang, PhD
University of Michigan Medical School
Ingrid Wertz, MD, PhD  Genentech
Ingrid Wertz, MD, PhD
Genentech
Benjamin Ebert, MD, PhD,  Dana-Farber Cancer Institute, Harvard Medical School
Benjamin Ebert, MD, PhD,
Dana-Farber Cancer Institute, Harvard Medical School
Paola Castaldi
Paola Castaldi, PhD,
AstraZeneca
Philip Chamberlain
Philip Chamberlain, D. Phil, Celgene